Description
Key facts
Detection method:Colorimetric,
Sample types:Cerebral Spinal Fluid, Milk, Plasma, Saliva, Serum, Urine,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:>= 1.2 ng/mL,
Range:3.125 - 200 ng/mL,
Assay time:4h,
Assay Platform:Microplate
Product details:
Human Apolipoprotein AI ELISA Kit (APOA1) ab108803 is a sandwich ELISA to measure Human Apolipoprotein AI (APOA1) in serum, plasma, cerebral spinal fluid (CSF), saliva, urine, milk with a sensitivity of 1.2 ng/ml.
How the assay works
An Apolipoprotein AI specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently an Apolipoprotein AI specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Complex is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Apolipoprotein AI captured in plate.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
Assay Specificity
Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details
Human Apolipoprotein AI ELISA Kit (APOA1) ab108803 protocol summary
1. Add standard or sample to appropriate wells. Incubate at room temperature
2. Wash and add prepared biotin antibody to each well. Incubate at room temperature.
3. Wash and add prepared Streptavidin-Peroxidase Conjugate. Incubate at room temperature
4. Add Chromogen Substrate to each well. Incubate at room temperature
5. Add Stop Solution to each well. Read at 450 nm immediately.
Get results in 90 minutes with our SimpleStep ELISA
Human Apolipoprotein AI ELISA Kit (ab189576)
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-I (ApoA-I) is a major component of high-density lipoprotein (HDL) particles often referred to as 'good cholesterol'. It has a molecular mass of approximately 28 kDa. ApoA-I is mainly expressed in the liver and intestine. It plays a mechanical role in the reverse transport of cholesterol acting to facilitate the efflux of cholesterol from tissues to the liver for excretion. Its alternative names include ApoAI ApoA1 and a component of the AI kits used for measuring this protein.
Biological function summary
ApoA-I functions in cholesterol homeostasis and inflammation. It is a structural component of the HDL complex that mobilizes cholesterol. ApoA-I acts as an activator of the enzyme lecithin-cholesterol acyltransferase (LCAT) which is essential for the maturation of HDL particles. This maturation is necessary for effective cholesterol transport and clearance. ApoA-I's ability to stabilize HDL particles and enhance their functionality makes it significant for maintaining lipid balance and cellular homeostasis.
Pathways
The interaction of ApoA-I with HDL formation and function marks its role in lipid metabolism pathways. Its participation in the reverse cholesterol transport pathway highlights its influence on cardiovascular health. ApoA-I also interacts with other proteins like ApoA-II and paraoxonase-1 which further influence lipid metabolism and antioxidant activities. Understanding these relationships helps elucidate the dynamics of cholesterol removal from the bloodstream.
Disturbances in ApoA-I levels correlate with cardiovascular disease and atherosclerosis. Deficiency or dysfunction in ApoA-I can impair HDL function leading to poor cholesterol removal and buildup within arteries. It is also connected to amyloidosis where misfolded ApoA-I forms deposits in tissues. Understanding these pathological conditions helps researchers target ApoA-I in therapeutic strategies to mitigate disease progression often studying it alongside proteins like ApoB which is associated with low-density lipoprotein (LDL) particles.
